Quantcast

Latest Lymphocytic Leukemia Stories

2014-02-27 18:40:45

A study led by Dr. Roderic Guigó from the Centre for Genomic Regulation in Barcelona, as part of the Chronic Lymphatic Leukaemia Genome Consortium, has made new advances in the study of this disease. The work, which was published (in print version) last week in the journal Genome Research, scrutinized the functional profile of the genes and mutations associated with leukemia. The Spanish Chronic Lymphatic Leukaemia Genome Consortium had previously identified the principal mutations...

2014-02-20 12:02:02

Babies who develop leukemia during the first year of life appear to inherit an unfortunate combination of genetic variations that can make the infants highly susceptible to the disease, according to a new study at Washington University School of Medicine in St. Louis and the University of Minnesota. The research is available online in the journal Leukemia. Doctors have long puzzled over why it is that babies just a few months old sometimes develop cancer. As infants, they have not lived...

2014-02-13 12:27:27

FLINT, Mich., Feb. 13, 2014 /PRNewswire-iReach/ -- Diplomat, the country's largest independent specialty pharmacy, announced today that IMBRUVICA(TM) (ibrutinib) was approved by the U.S. Food and Drug Administration (FDA) for the treatment of chronic lymphocytic lymphoma (CLL) in patients who have received at least one prior therapy. An improvement in survival or disease-related symptoms has not been established. IMBRUVICA(TM), a Bruton's tyrosine kinase (BTK) inhibitor, is an oral...

2014-02-12 16:25:59

HORSHAM, Pa., Feb. 12, 2014 /PRNewswire/ -- Janssen Biotech, Inc. ["Janssen"] today announced the U.S. Food and Drug Administration (FDA) has approved IMBRUVICA(TM) (ibrutinib) capsules for the treatment of patients with chronic lymphocytic leukemia (CLL) who have received at least one prior therapy.(1) IMBRUVICA was first approved in November 2013 for the treatment of patients with mantle cell lymphoma (MCL) who have received at least one prior therapy.(1) Both indications are based...

2014-02-12 12:32:40

SUNNYVALE, Calif., Feb. 12, 2014 /PRNewswire/ -- Pharmacyclics, Inc. (NASDAQ: PCYC) today announced that the U.S. Food and Drug Administration (FDA) has approved IMBRUVICA((TM)) (ibrutinib) as a single agent for the treatment of patients with chronic lymphocytic leukemia (CLL) who have received at least one prior therapy.(1) This indication is based on overall response rate (ORR). An improvement in survival or disease-related symptoms has not been established.(1) IMBRUVICA is the first...

2014-02-12 08:22:51

DUBLIN, Feb. 12, 2014 /PRNewswire/ -- Research and Markets ( http://www.researchandmarkets.com/research/x4z6dv/acute ) has announced the addition of the "Acute Lymphocytic/Lymphoblastic Leukemia Therapeutics Market - Pipeline Forecast & Market Forecast in G8 Countries to 2020" report to their offering. (Logo: http://photos.prnewswire.com/prnh/20130307/600769) The acute lymphocytic/lymphoblastic leukemia therapeutics market is segmented based on existing regimens and drugs, pipeline...

2014-02-03 23:02:17

Ibrutinib, a small molecule inhibitor of Bruton’s tyrosine kinase, will be investigated in combination with rituximab by the ECOG-ACRIN Cancer Research Group in its latest clinical trial, E1912. Philadelphia, PA (PRWEB) February 03, 2014 The ECOG-ACRIN Cancer Research Group (ECOG-ACRIN) announced today that it has activated E1912, a randomized phase III clinical trial to evaluate the ability of the combination of ibrutinib and rituximab to prolong progression-free survival in previously...

2014-01-24 11:25:34

Results on test of Idelalisib suggest CLL may be treated without toxic chemotherapy Use of a twice-daily pill could turn a deadly blood cancer into a highly treatable disease, according to scientists at Weill Cornell Medical College who led a multinational research team. Their findings on the therapy for chronic lymphocytic leukemia (CLL), reported in the Jan. 22 issue of the New England Journal of Medicine, suggest that patients may be able to avoid having to take debilitating...

2014-01-23 16:24:44

Grant Program Addresses Three Critical Areas of Blood Cancer Research WHITE PLAINS, N.Y., Jan. 23, 2014 /PRNewswire/ -- The Leukemia & Lymphoma Society (LLS) today is pleased to announce the fourteen researchers who will receive funding through the Quest for Cures program - a new grant program that addresses three critical areas of blood cancer research. The three priority areas are: monitoring tumor cell heterogeneity and its contribution to response or resistance to therapy; molecular...

2014-01-21 23:21:44

Acute Lymphocytic / Lymphoblastic Leukemia Therapeutics Market report categorizes the market in G8 countries into the following segments by Drug and by Geography. http://www.marketsandmarkets.com/Market-Reports/acute-lymphocytic-leukemia-therapeutics-market-518.html (PRWEB) January 21, 2014 The “Acute Lymphocytic/Lymphoblastic Leukemia Therapeutics Market - (Pipeline Forecast & Market Forecast in G8 Countries) (2010 - 2020)” analyzes and studies the major market drivers,...


Word of the Day
tesla
  • The unit of magnetic flux density in the International System of Units, equal to the magnitude of the magnetic field vector necessary to produce a force of one newton on a charge of one coulomb moving perpendicular to the direction of the magnetic field vector with a velocity of one meter per second. It is equivalent to one weber per square meter.
This word is named for Nikola Tesla, the inventor, engineer, and futurist.